695 related articles for article (PubMed ID: 19160091)
1. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
2. Comparative promoter methylation analysis of p53 target genes in urogenital cancers.
Christoph F; Hinz S; Weikert S; Kempkensteffen C; Schostak M; Miller K; Schrader M
Urol Int; 2008; 80(4):398-404. PubMed ID: 18587251
[TBL] [Abstract][Full Text] [Related]
3. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of DNA methylation is associated with tumor stage in gastric cancer.
Oue N; Mitani Y; Motoshita J; Matsumura S; Yoshida K; Kuniyasu H; Nakayama H; Yasui W
Cancer; 2006 Mar; 106(6):1250-9. PubMed ID: 16475210
[TBL] [Abstract][Full Text] [Related]
5. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
7. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer.
Sobti RC; MalekZadeh K; Nikbakht M; Sadeghi IA; Shekari M; Singh SK
Biomarkers; 2010 Mar; 15(2):167-74. PubMed ID: 19958159
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
10. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
11. Methyl-CpG-binding domain 2: a protective role in bladder carcinoma.
Zhu Y; Spitz MR; Zhang H; Grossman HB; Frazier ML; Wu X
Cancer; 2004 May; 100(9):1853-8. PubMed ID: 15112265
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of multiple genes in astrocytic gliomas.
Gonzalez-Gomez P; Bello MJ; Arjona D; Lomas J; Alonso ME; De Campos JM; Vaquero J; Isla A; Gutierrez M; Rey JA
Int J Oncol; 2003 Mar; 22(3):601-8. PubMed ID: 12579314
[TBL] [Abstract][Full Text] [Related]
15. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
16. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
17. Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
Marsit CJ; Karagas MR; Danaee H; Liu M; Andrew A; Schned A; Nelson HH; Kelsey KT
Carcinogenesis; 2006 Jan; 27(1):112-6. PubMed ID: 15987713
[TBL] [Abstract][Full Text] [Related]
18. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
19. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
20. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
